A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD of ELX-02 in Cystic Fibrosis Patients With G542X Allele

Name: A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD of ELX-02 in Cystic Fibrosis Patients With G542X Allele
Published: 2019
License: Public Domain

Eloxx Pharmaceuticals, Inc. · 2019

ClinicalTrials.gov · Datasets · License: Public Domain · 2019

Open Source ↗

cystic-fibrosis

cystic fibrosis, elx-02, g542x allele, eukaryotic ribosomal selective glycoside, interventional, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD of ELX-02 in Cystic Fibrosis Patients With G542X Allele

Related documents